Testing a new drug to preserve insulin production in type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new drug called SAB-142, which aims to stop the immune system from attacking insulin-making cells in type 1 diabetes. It may help preserve your body's ability to make insulin. The trial will check if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 15 and 40 years old (or 5 to 40 for part B) and weigh at least 16 kg.
- You must have been diagnosed with type 1 diabetes within the last 100 days.
- You must test positive for at least one diabetes-related autoantibody (GAD65, IA-2, ZnT8, or insulin).
- You must not have certain medical conditions like active infections, liver problems, blood count abnormalities, or recent use of immune-altering drugs.
- Women must not be pregnant or breastfeeding and must use contraception if applicable.
- You must be willing to follow the study schedule and avoid other experimental treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a low dose of a drug that calms the immune system, followed by either another immune drug or a blood pressure medicine, to see if they can help preserve the body's ability to make insulin in people recently diagnosed with type 1 diabetes. It may help keep your own insulin production going longer.
This trial tests an investigational drug that may help preserve the body's ability to make insulin in people with type 1 diabetes. It aims to slow the progression of the disease and reduce the need for insulin injections.
This study tests if denosumab, a drug normally used for bone health, can help preserve your body's own insulin production in type 1 diabetes. It might slow the loss of insulin-making cells, helping you maintain better blood sugar control over time.
This early-stage study tests an investigational insulin (HDV-insulin lispro) given by injection, to see how it affects glucose production in the liver and overall blood sugar control. Participation involves dose-response testing and monitoring, which may help guide future diabetes treatment.
This Phase 1/2 study tests whether CELZ-201 is safe and can help the body keep making some of its own insulin in people who were recently diagnosed with type 1 diabetes. You may be eligible if your diabetes started within the past year and your tests show you still have some insulin-making activity.
This study tests a system that measures blood sugar and automatically adjusts insulin delivery. It is for adults with type 1 diabetes who use insulin injections or a pump.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.